187 related articles for article (PubMed ID: 21135272)
1. Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.
Tapper W; Chiecchio L; Dagrada GP; Konn ZJ; Stockley DM; Szubert AJ; Gregory WM; Bell SE; Jackson GH; Child JA; Morgan GJ; Ross FM
J Clin Oncol; 2011 Jan; 29(2):e37-9; author reply e40-1. PubMed ID: 21135272
[No Abstract] [Full Text] [Related]
2. Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma.
Hung D; Lenton D; Eslick R; Blennerhassett R; Joshi M; McCaughan G; Day S; Wright D
Genes Chromosomes Cancer; 2021 Oct; 60(10):668-677. PubMed ID: 34041820
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndrome with isochromosome 5p and trisomy 8 after treatment of a multiple myeloma.
Jimenez-Sousa MA; Ferro MT; Talavera M; Villalon C; Cabello P; Laraña J; Herrera P; Garcia Sagredo JM
Cancer Genet Cytogenet; 2010 Dec; 203(2):345-7. PubMed ID: 21156257
[No Abstract] [Full Text] [Related]
4. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens.
Grzasko N; Hus M; Chocholska S; Pluta A; Hajek R; Dmoszynska A
Leuk Lymphoma; 2012 Dec; 53(12):2500-3. PubMed ID: 22497640
[No Abstract] [Full Text] [Related]
5. Analysis of chromosome 12p deletion in plasma cell dyscrasias.
Jiang N; Qi C; Yu L; Ning Y; An G; Qiu L; Chang H
Leuk Res; 2012 Jan; 36(1):32-6. PubMed ID: 21982640
[TBL] [Abstract][Full Text] [Related]
6. Therapy-related myelodysplastic syndrome. Two cytogenetically unrelated abnormal clones in a patient with multiple myeloma.
Abeliovich D; Yehuda O; Ben-Neriah S; Matzner Y
Cancer Genet Cytogenet; 1993 Oct; 70(2):117-9. PubMed ID: 8242590
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
Bahmanyar M; Qi X; Chang H
Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of 8p21 deletion in multiple myeloma.
Sutlu T; Alici E; Jansson M; Wallblom A; Dilber MS; Gahrton G; Nahi H
Br J Haematol; 2009 Jan; 144(2):266-8. PubMed ID: 19016723
[No Abstract] [Full Text] [Related]
11. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
13. [Chromosome findings in multiple myeloma].
Suzuki K
Nihon Rinsho; 1995 Mar; 53(3):568-73. PubMed ID: 7699887
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetics of multiple myeloma.
Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
[TBL] [Abstract][Full Text] [Related]
15. [Cytogenetic and clinical characteristics in 31 cases of blood diseases with aberrations at short arm of chromosome 12].
Zhang Y; Qiu JY; He Q; Shi Y; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):166-9. PubMed ID: 15157326
[TBL] [Abstract][Full Text] [Related]
16. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
[TBL] [Abstract][Full Text] [Related]
17. [Cytogenetic study of multiple myeloma].
Zhang Y; Jiang B; Huang XJ; Shi Y; He Q; Dang H; Qiu JY; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):76-8. PubMed ID: 17490526
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in multiple myeloma.
Magrangeas F; Lodé L; Wuilleme S; Minvielle S; Avet-Loiseau H
Leukemia; 2005 Feb; 19(2):191-4. PubMed ID: 15538406
[TBL] [Abstract][Full Text] [Related]
19. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
Lange K; Gadzicki D; Schlegelberger B; Göhring G
Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
[TBL] [Abstract][Full Text] [Related]
20. Chromosome 9 interstitial deletion in multiple myeloma.
Ferro MT; Hernaez R; Villalon C; Sordo MT; Garcia-Sagredo JM; Vallcorba I; Roman CS; Lopez J
Cancer Genet Cytogenet; 2002 Nov; 139(1):88-9. PubMed ID: 12547169
[No Abstract] [Full Text] [Related]
[Next] [New Search]
